SARS-CoV-2 structural features may explain limited neutralizing-antibody responses

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

(2020) Daniel Blanco-Melo et al.   CELL

The 3Ds in virus-like particle based-vaccines: “Design, Delivery and Dynamics ”

(2020) Mona O. Mohsen et al.   IMMUNOLOGICAL REVIEWS

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

(2020) Rui Shi et al.   NATURE

Human neutralizing antibodies elicited by SARS-CoV-2 infection

(2020) Bin Ju et al.   NATURE

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

(2020) Irani Thevarajan et al.   NATURE MEDICINE

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

(2020) Christopher O. Barnes et al.   CELL

Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses

(2020) Runhong Zhou et al.   IMMUNITY

Lessons for COVID-19 Immunity from Other Coronavirus Infections

(2020) Alan Sariol et al.   IMMUNITY

Direct Observation of Repeated Infections With Endemic Coronaviruses

(2020) Marta Galanti et al.   JOURNAL OF INFECTIOUS DISEASES

New IgM seroconversion and positive RT‐PCR test after exposure to the virus in recovered COVID‐19 patient

(2020) Enrico Bentivegna et al.   JOURNAL OF MEDICAL VIROLOGY

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

(2020) Philip J. M. Brouwer et al.   SCIENCE

Interplay between SARS-CoV-2 and the type I interferon response

(2020) Margarida Sa Ribero et al.   PLoS Pathogens

Accuracy of serological testing for SARS‐CoV‐2 antibodies: first results of a large mixed‐method evaluation study

(2020) D. Brigger et al.   ALLERGY

Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19

(2020) Benjamin J. Meckiff et al.   CELL

What can we expect from first-generation COVID-19 vaccines?

(2020) Malik Peiris et al.   LANCET

Coronavirus reinfections: three questions scientists are asking

(2020) Heidi Ledford   NATURE

Humoral Immune Response to SARS-CoV-2 in Iceland

(2020) Daniel F. Gudbjartsson et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Power of Antibody-Based Surveillance

(2020) Galit Alter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

(2020) Cheryl Keech et al.   NEW ENGLAND JOURNAL OF MEDICINE

Susceptibility to severe COVID-19

(2020) David B. Beck et al.   SCIENCE

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

(2020) Paul Bastard et al.   SCIENCE

Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition

(2020) Oliver C. Grant et al.   Scientific Reports

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

(2020) Jeffrey Seow et al.   Nature Microbiology

Mass Spectrometry Analysis of Newly Emerging Coronavirus HCoV-19 Spike Protein and Human ACE2 Reveals Camouflaging Glycans and Unique Post-Translational Modifications

(2020) Zeyu Sun et al.   Engineering

Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses

(2019) Mark K. Slifka et al.   Frontiers in Immunology

Longitudinal study of Middle East Respiratory Syndrome coronavirus infection in dromedary camel herds in Saudi Arabia, 2014–2015

(2017) Maged Gomaa Hemida et al.   Emerging Microbes & Infections

Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus

(2014) Marion Sevajol et al.   VIRUS RESEARCH

Innate Immunity Mediates Follicular Transport of Particulate but Not Soluble Protein Antigen

(2012) A. Link et al.   JOURNAL OF IMMUNOLOGY

Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology

(2010) Jody D. Berry et al.   mAbs